ArticleFrontiers in bioengineering and biotechnology2025
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: With an average of 6.8 million fractures per year in the United States, the current method for surgical intervention involves bioinert materials that do not promote osteogenesis and can have inflammatory reactions that hinder bone healing. Magnesium has emerged in research due to the material's biodegradability and biocompatibility; however, it has a low corrosion resistance, which can lead to hydrogen gas evolution and tissue necrosis. Therefore, magnesium is typically alloyed with rare earth elements (REEs) to increase corrosion resistance. The main goal of this study involves fabricating a magnesium (Mg)-based metal matrix nanocomposite (MMNC) containing scandium (Sc) and strontium (Sr) as alloying elements, as well as diopside (CaMgSi2O6) -based bioactive glass-ceramic nanoparticles for reinforcement. Methods: MMNCs were processed using ultrasonic melt processing and hot rolling to disperse nanoparticles and refine their microstructure. These MMNCs have undergone detailed tests to determine microstructure and degradation properties, followed by Results: Through cell culture with human bone marrow-derived mesenchymal stem cells (hBM-MSCs) we determined that MMNCs provide Discussion: This allows for an understanding of potential applications of our composite as a biomaterial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.